Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study

NCT02396043 Phase 2 UNKNOWN

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.

Details

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	UNKNOWN
Enrolment	50
Start date	2015-03
Completion	2025-03

Conditions

• Lymphoma, Lymphoblastic

Interventions

• induction phase1
• induction phase2
• protocol M
• maintenance therapy
• reinduction phase1
• reinduction phase2
• Intrathecal (IT)

Primary outcomes

• progression free survival — up to end of follow-up-phase (approximately 3 years)

Countries

China